MTOR and carcinoma: We then tested drugs approved for advanced neuroendocrine tumors and carcinomas, including somatostatin analogs (octreotide, lanreotide, pasireotide), the multikinase-inhibitor sunitinib, the mTOR-inhibitor everolimus as well as conventional chemotherapeutics (5-FU, cisplatin, etoposide, carboplatin).